US 12,435,325 B2
RNA-guided nucleases and active fragments and variants thereof and methods of use
Gunjan H. Arya, Cary, NC (US); Michael Coyle, Chapel Hill, NC (US); Alexandra Briner Crawley, Cary, NC (US); Tedd D. Elich, Durham, NC (US); and Joel S. Parker, Apex, NC (US)
Assigned to Life Edit Therapeutics, Inc., Durham, NC (US)
Filed by Life Edit Therapeutics, Inc., Durham, NC (US)
Filed on Jul. 23, 2024, as Appl. No. 18/781,699.
Application 18/781,699 is a continuation of application No. PCT/IB2023/050560, filed on Jan. 23, 2023.
Claims priority of provisional application 63/386,061, filed on Dec. 5, 2022.
Claims priority of provisional application 63/302,271, filed on Jan. 24, 2022.
Prior Publication US 2024/0376456 A1, Nov. 14, 2024
Int. Cl. C12N 9/22 (2006.01); A61K 48/00 (2006.01); C12N 9/12 (2006.01); C12N 9/78 (2006.01); C12N 15/11 (2006.01); C12N 15/63 (2006.01); C12N 15/90 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/22 (2013.01) [A61K 48/005 (2013.01); C12N 9/1252 (2013.01); C12N 9/1276 (2013.01); C12N 9/78 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/63 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01); C12N 2310/20 (2017.05); C12Y 305/04001 (2013.01); C12Y 305/04002 (2013.01)] 30 Claims
 
1. A nucleic acid molecule comprising a polynucleotide encoding an RNA-guided nuclease (RGN) polypeptide, wherein said RGN polypeptide comprises an amino acid sequence having at least 90% sequence identity across the full length of SEQ ID NO: 6; wherein said polynucleotide encoding an RGN polypeptide is operably linked to a promoter heterologous to said polynucleotide.